Day: October 24, 2025
Q3: continued sales and earnings progress
Paris, October 24, 2025
Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and AyvakitDupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarterVaccines sales decreased by 7.8% to €3.4 billion, from lower influenza salesResearch and Development expenses were €1.8 billion, an increase of 4.9%Selling, general and administrative expenses were €2.3 billion, up 7.1% to support launchesBusiness EPS was €2.91, up 13.2% at CER and 7.0% at actual exchange rates, delivering profitable growth; IFRS EPS was €2.30Pipeline progressTwo regulatory approvals: Wayrilz (US) in ITP, a rare disease, and Tzield (China) for delaying onset of stage 3, type...
Prospectus Approved for Listing of DNO’s USD 400 Million Hybrid Bonds on Oslo Stock Exchange
Written by Customer Service on . Posted in Public Companies.
Oslo, 24 October 2025 – DNO ASA, the Norwegian oil and gas operator, today announced that the Financial Supervisory Authority of Norway on 23 October 2025 approved the prospectus prepared in connection with the listing on the Oslo Stock Exchange of the Company’s 10.75 percent USD 400 million subordinated hybrid callable bonds issued on 17 June 2025 with maturity in June 2085 (ISIN: NO0013582627). Trading in the bonds is expected to commence today.
The prospectus dated 23 October 2025 is available on the Company’s website www.dno.no.
–
For further information, please contact:Media: media@dno.noInvestors: investor.relations@dno.no
–
DNO ASA is a Norwegian oil and gas operator active in the Middle East, the North Sea and West Africa. Founded in 1971, DNO is Norway’s oldest oil company and the first to list on the Oslo Stock Exchange...
Norsk Hydro: Solid results amid uncertain markets
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Hydro’s adjusted EBITDA for the third quarter of 2025 was NOK 5,996 million, down from NOK 7,367 million in the same quarter last year. The results decreased from lower realized alumina prices and a stronger NOK. This was partly offset by higher primary and alumina volumes, positive gain from increasing U.S. Midwest premium in Extrusions (metal effect) and realization of previously eliminated internal profits. Hydro generated NOK 2.2 billion in free cash flow, while the twelve month adjusted RoaCE ended at 11 percent.Solid cash generation, uncertain extrusion marketsExecuting on strategic workforce and cost reductionsFuture proofing Alouette by signing an Agreement in Principle for long-term power contract until 2045Dutch court dismisses all claims against Hydro filed by Brazilian Cainquiama and nine individuals in 2021Advancing...
Signify reports third quarter sales of EUR 1.4 billion, operational profitability of 9.7% and a free cash flow of EUR 71 million
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Press Release
October 24, 2025
Signify reports third quarter sales of EUR 1.4 billion, operational profitability of 9.7% and a free cash flow of EUR 71 million
Third quarter 20251Signify’s installed base of connected light points increased to 160 million in Q3 25
On track for three Brighter Lives, Better World 2025 sustainability program commitments
Sales of EUR 1,407 million; nominal sales of -8.4%
Comparable Sales Growth (CSG) of -3.9%; -2.7% excluding the Conventional business
Adj. EBITA margin of 9.7% (Q3 24: 10.5%)
Net income of EUR 76 million (Q3 24: EUR 108 million)
Free cash flow of EUR 71 million (Q3 24: EUR 119 million)
Share repurchase program on track; EUR 116.4 million of shares repurchased until September 30, 2025Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced...
Hiab’s interim report January–September 2025: Profitability affected by lower sales in the US
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
HIAB CORPORATION, INTERIM REPORT JANUARY–SEPTEMBER 2025, 24 OCTOBER 2025 AT 8:00 AM (EEST)
Hiab’s interim report January–September 2025: Profitability affected by lower sales in the US
Highlights of the quarterOrders received decreased slightly from the comparison period to EUR 351 (361) million
Comparable operating profit margin decreased to 11.4 (13.4) percent due to lower sales in the US
Elevated market uncertainty due to increased trade tensions continued
Services sales increased by 4 percent to EUR 116 (112) million
Sale of MacGregor was closed on 31 JulyUnless otherwise stated, the financial information in this report concerns Hiab’s continuing operations. This interim report is unaudited.
July–September 2025 in brief: Share of Services increased to 34 percentOrders received decreased by 3 percent and totalled...
Nokia extends long-term partnership with VNPT in Vietnam
Written by Customer Service on . Posted in Public Companies.
Press Release Nokia extends long-term partnership with VNPT in VietnamCompanies sign deal extension to upgrade VNPT’s radio infrastructure across the Hanoi area, border provinces, and the South of Vietnam.
Deployment of Nokia’s advanced AirScale equipment portfolio will enhance connectivity and increase network capacity.
Deal aims to further improve mobile coverage, accelerate digital transformation and contribute to Vietnam’s socio-economic development.24 October 2025Espoo, Finland – Nokia today announced the extension of its long-term partnership with Vietnam Posts and Telecommunications Group (VNPT), one of Vietnam’s leading telecommunications operators, through a new agreement to upgrade and expand radio infrastructure across Vietnam. The new deal focuses on the Hanoi area, border provinces, and the southern...
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
Written by Customer Service on . Posted in Public Companies.
BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to X4 from the offering are expected to be approximately $135 million before deducting underwriting discounts and commissions and other offering expenses payable by X4, excluding...
RESILIENT PERFORMANCE IN FIRST NINE MONTHS – STRATEGIC ACTIONS TO DRIVE GROWTH AND PROFITABILITY
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Ad Hoc Announcement Pursuant to Article 53 of the SIX Exchange Regulation Listing Rules RESILIENT PERFORMANCE IN FIRST NINE MONTHS – STRATEGIC ACTIONS TO DRIVE GROWTH AND PROFITABILITY Sales increase of 1.1% in local currencies in the first nine months despite a double-digit decline in China’s construction business; foreign currency impact of -4.9% primarily due to weaker US dollar
Material margin increases to 55.0% (previous year: 54.7%) and EBITDA margin rises to 19.2% (previous year: 19.1%)
Key investments reinforce the Group’s market position: five acquisitions and seven new factories
MBCC integration completed, realization of increased synergies on track
Sika is making structural adjustments in ongoing weak markets, such as China, with anticipated one-off costs of CHF 80 to 100 million, incurring in 2025. The measures include a...
